Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
Shepherd
J
J
Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland.
Olsson
A G
AG
Sacks
F M
FM
Black
D M
DM
Orloff
D G
DG
Bilheimer
D W
DW
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control; D002986:Clinical Trials as Topic / Q000379:methods*; D004341:Drug Evaluation / Q000379:methods*; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D011859:Radiography; D012449:Safety; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D008055:Lipids